The diabetes medication semaglutide, known under brand names like Ozempic, Wegovy, and Rybelsus, has garnered attention not only for its weight loss capabilities but also for significant cardiovascular benefits. A recent meta-analysis published in the International Journal of Obesity illustrates the multifaceted advantages of semaglutide, showcasing its potential in reducing cardiovascular risks associated with diabetes.
According to the findings, semaglutide usage leads to notable reductions in various cardiovascular issues, such as:
- 17% decrease in deaths related to cardiovascular disease
- 76% reduction in hospitalizations due to heart failure
- 24% fewer non-fatal heart attacks
- 24% reduction in the need for coronary revascularization
- 35% decrease in strokes among people with diabetes
- 21% decline in all-cause mortality
Determining the specific contribution of semaglutide versus that of weight loss presents challenges due to the interlinked nature of these factors. The meta-analysis included 38 studies covering diverse patient groups, both with and without diabetes. Notably, those on higher doses of semaglutide reported more gastrointestinal side effects, with the 2.4 mg doses resulting in the greatest challenges.
However, these side effects do not negate the drug’s cardiovascular benefits. Renowned cardiologist Dr. Jayne Morgan emphasized that semaglutide’s mechanisms, such as stabilizing atherosclerotic plaques and improving systemic inflammation related to obesity, directly contribute to its heart health benefits.
In terms of application, the meta-analysis also highlighted that oral semaglutide demonstrated better outcomes in reducing all-cause mortality compared to its subcutaneous counterpart. This could be attributed to enhanced adherence and fewer side effects associated with the oral administration.
While gastrointestinal side effects are common with semaglutide, researchers suggest managing these issues through gradual dose adjustments and dietary modifications. For example, starting with lower doses and allowing time for the body to adapt may alleviate discomfort. Additionally, focusing on protein and vegetable intake can facilitate weight loss and minimize adverse effects.
The results of this meta-analysis underscore the importance of viewing obesity treatment as a chronic condition, akin to diabetes and hypertension. Continuous treatment is vital for long-term success and weight management. The implications of semaglutide’s direct cardiovascular benefits also raise important questions regarding its potential value for individuals at risk of cardiovascular diseases, whether or not they have diabetes or are overweight.
Source: MedicalNewsToday
